Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of CRTE7A2-01 TCR-T Cells in HLA-A*02:01+ Subjects With HPV16 Positive Advanced Cervical, Anal, or Head and Neck Cancers and Other Solid Tumors

NCT06358053 is registered in ClinicalTrials.gov with Corregene Biotechnology Co., Ltd as lead sponsor.

NCT NCT06358053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06358053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of CRTE7A2-01 TCR-T Cells in HLA-A*02:01+ Subjects With HPV16 Positive Advanced Cervical, Anal, or Head and Neck Cancers and Other Solid Tumors
Lead sponsor
Corregene Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 15, 2024
Completion date
April 30, 2028
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, cervical cancer, head and neck cancers, other solid tumors